JP2015508063A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508063A5
JP2015508063A5 JP2014554950A JP2014554950A JP2015508063A5 JP 2015508063 A5 JP2015508063 A5 JP 2015508063A5 JP 2014554950 A JP2014554950 A JP 2014554950A JP 2014554950 A JP2014554950 A JP 2014554950A JP 2015508063 A5 JP2015508063 A5 JP 2015508063A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
antibody
seq
asic1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014554950A
Other languages
English (en)
Japanese (ja)
Other versions
JP6302844B2 (ja
JP2015508063A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/023784 external-priority patent/WO2013116296A1/en
Publication of JP2015508063A publication Critical patent/JP2015508063A/ja
Publication of JP2015508063A5 publication Critical patent/JP2015508063A5/ja
Application granted granted Critical
Publication of JP6302844B2 publication Critical patent/JP6302844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014554950A 2012-01-31 2013-01-30 抗asic1抗体及びその使用 Active JP6302844B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US61/592,837 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US61/644,038 2012-05-08
US201261692925P 2012-08-24 2012-08-24
US61/692,925 2012-08-24
PCT/US2013/023784 WO2013116296A1 (en) 2012-01-31 2013-01-30 Anti-asic1 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2015508063A JP2015508063A (ja) 2015-03-16
JP2015508063A5 true JP2015508063A5 (enExample) 2016-03-10
JP6302844B2 JP6302844B2 (ja) 2018-03-28

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014554950A Active JP6302844B2 (ja) 2012-01-31 2013-01-30 抗asic1抗体及びその使用

Country Status (33)

Country Link
US (3) US9150648B2 (enExample)
EP (2) EP3453723B1 (enExample)
JP (1) JP6302844B2 (enExample)
KR (1) KR102111941B1 (enExample)
CN (1) CN104093738B (enExample)
AR (1) AR089852A1 (enExample)
AU (1) AU2013215254B2 (enExample)
CA (1) CA2862332C (enExample)
CL (1) CL2014002019A1 (enExample)
CO (1) CO7020877A2 (enExample)
CY (2) CY1121368T1 (enExample)
DK (2) DK2809681T3 (enExample)
EA (1) EA028647B1 (enExample)
ES (2) ES2707599T3 (enExample)
HR (2) HRP20190358T1 (enExample)
HU (2) HUE056335T2 (enExample)
IL (2) IL233410A0 (enExample)
IN (1) IN2014CN04645A (enExample)
JO (1) JO3547B1 (enExample)
LT (2) LT2809681T (enExample)
MX (1) MX358518B (enExample)
MY (1) MY168748A (enExample)
NZ (1) NZ626242A (enExample)
PH (1) PH12014501613A1 (enExample)
PL (2) PL3453723T3 (enExample)
PT (2) PT3453723T (enExample)
RS (2) RS62454B1 (enExample)
SG (1) SG11201403222UA (enExample)
SI (2) SI2809681T1 (enExample)
SM (1) SMT202100628T1 (enExample)
TW (1) TWI591073B (enExample)
UY (1) UY34603A (enExample)
WO (1) WO2013116296A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2809681T3 (en) 2012-01-31 2019-03-11 Regeneron Pharma ANTI-ASIC1 antibodies and uses thereof
JP2017513854A (ja) 2014-04-15 2017-06-01 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. Wisp1に結合する抗原結合タンパク質
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
HUE050007T2 (hu) 2014-05-16 2020-11-30 Ablynx Nv Immunglobulin variábilis domének
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
EP3980456A4 (en) * 2019-06-04 2023-01-18 Shanghaitech University AFFINITY MATURING ANTI-ASIC1A ANTIBODIES
BR112022000216A2 (pt) 2019-07-11 2022-05-17 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a dll3 e usos dos mesmos
WO2021012176A1 (en) * 2019-07-23 2021-01-28 Shanghaitech University Asic1 channel antagonist antibody
CA3154387A1 (en) * 2019-09-13 2021-03-18 Tri-Institutional Therapeutics Discovery Institute, Inc. Anti-cd371 antibodies and uses thereof
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
JP2024534892A (ja) * 2021-09-02 2024-09-26 メモリアル スローン ケタリング キャンサー センター 抗dll3抗体及びその使用
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
ES2279583T3 (es) 1997-10-29 2007-08-16 Mcgill University Adn que codifica para un canal ionico regulado por protones humano y usos del mismo.
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CN1326879C (zh) * 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
CA2538754A1 (en) 2003-09-11 2005-03-24 The Uab Research Foundation Inhibition of inward sodium currents in cancer
WO2005074923A1 (en) 2004-02-03 2005-08-18 Agt Biosciences Limited Methods and compositions
EP1734962A4 (en) 2004-03-30 2010-07-14 Painceptor Pharma Corp COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
WO2006068953A2 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
KR101203328B1 (ko) * 2005-04-26 2012-11-20 화이자 인코포레이티드 P-카드헤린 항체
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
EP2078732B1 (en) * 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
US8618113B2 (en) 2006-07-14 2013-12-31 Medical Research Council Treatment for demyelinating disease
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
DK2137539T3 (da) 2007-04-03 2011-01-24 Ilegusavnid Genetics Resource Ct Minestry Of Social Affairs And Health Amolorid følsomme calciumkanaler forbundet med paniklidelser
CA2683145C (en) * 2007-04-27 2018-06-12 Katherine E. Lewis Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2288922B1 (en) * 2008-05-08 2016-08-17 University of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
DK2809681T3 (en) 2012-01-31 2019-03-11 Regeneron Pharma ANTI-ASIC1 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2015508063A5 (enExample)
JP2014530215A5 (enExample)
JP2017505125A5 (enExample)
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
JP2015503909A5 (enExample)
JP2018536393A5 (enExample)
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
RU2011116112A (ru) Биспецифические анти-egfr/анти-igf-1r антитела
JP2015514110A5 (enExample)
JP2017508475A5 (enExample)
JP2011184466A5 (enExample)
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
JP2014205674A5 (enExample)
JP2015517300A5 (enExample)
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
JP2018052979A5 (enExample)
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
RU2016124179A (ru) СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека
JP2013529183A5 (enExample)
BR112012019098A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo
HRP20231514T1 (hr) Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka
JP2017507657A5 (enExample)
CA2793647A1 (en) Prophylaxis of colorectal and gastrointestinal cancer
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)